Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2MZF8
|
|||
| Drug Name |
TAK-102
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Takeda
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glypican-3 (GPC3) | Target Info | . | [1] |
| KEGG Pathway | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Glypican pathway | |||
| Glypican 3 network | ||||
| Reactome | A tetrasaccharide linker sequence is required for GAG synthesis | |||
| HS-GAG degradation | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.